We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ZEPOSIA (Celgene Pty Ltd)
Product name
ZEPOSIA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
218 working days (255)
Active ingredients
ozanimod hydrochloride
Registration type
NCE/NBE
Indication
ZEPOSIA (capsule) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis.